AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
12 Jun 2018 07:00 AM
RNS
Update: lanabecestat Phase III Alzheimer's trials
08 Jun 2018 05:30 PM
RNS
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
08 Jun 2018 07:00 AM
RNS
Director Declaration
01 Jun 2018 03:00 PM
RNS
Block listing Interim Review
01 Jun 2018 03:00 PM
RNS
Total Voting Rights
01 Jun 2018 11:00 AM
RNS
Director Declaration
30 May 2018 07:00 AM
RNS
Update on TERRANOVA PIII trial for Fasenra in COPD
25 May 2018 07:00 AM
RNS
AZ's Imfinzi: significant OS in Stage III nsclc
21 May 2018 07:00 AM
RNS
AZ regulatory submission in Japan for Forxiga
21 May 2018 07:00 AM
RNS
US FDA approves Lokelma for adult hyperkalaemia
18 May 2018 05:30 PM
RNS
Result of AGM
18 May 2018 07:00 AM
RNS
AZN: Q1 2018 Results
11 May 2018 07:00 AM
RNS
AstraZeneca update on Fasenra PIII trial in COPD
08 May 2018 11:00 AM
RNS
EMA approves Lynparza: maintenance ovarian cancer
08 May 2018 07:00 AM
RNS
AZ and Luye Pharma enter agreement for Seroquel
04 May 2018 12:00 PM
RNS
Director Declaration
01 May 2018 03:00 PM
RNS
Total Voting Rights
27 Apr 2018 12:30 PM
RNS
AZ: positive CHMP for Tagrisso first-line nsclc
24 Apr 2018 07:00 AM
RNS
AstraZeneca:high level results of the ARCTIC trial
19 Apr 2018 07:00 AM
RNS
FDA approves Tagrisso for 1st-line use in NSCLC
13 Apr 2018 11:00 AM
RNS
Notice of AGM
05 Apr 2018 07:00 AM
RNS
Directorate Change
03 Apr 2018 03:00 PM
RNS
Total Voting Rights
03 Apr 2018 07:00 AM
RNS
AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
03 Apr 2018 07:00 AM
RNS
FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
28 Mar 2018 03:00 PM
RNS
Director/PDMR Shareholding
26 Mar 2018 03:00 PM
RNS
Director/PDMR Shareholding
22 Mar 2018 04:48 PM
RNS
Lokelma approved in the EU
12 Mar 2018 07:00 AM
RNS
ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
07 Mar 2018 07:00 AM
RNS
Filing of Form 20-F with SEC
06 Mar 2018 11:00 AM
RNS
Annual Financial Report
01 Mar 2018 03:00 PM
RNS
Total Voting Rights
23 Feb 2018 12:35 PM
RNS
Lynparza CHMP for ovarian cancer maintainance
19 Feb 2018 07:00 AM
RNS
AstraZeneca's IMFINZI approved for Stage III nsclc
15 Feb 2018 07:00 AM
RNS
Selumetinib in NF1 gets FDA orphan drug status
05 Feb 2018 02:00 PM
RNS
Director/PDMR Shareholding
02 Feb 2018 07:00 AM
RNS
AZN: Full-Year 2017 Results
01 Feb 2018 03:00 PM
RNS
Total Voting Rights
26 Jan 2018 06:20 PM
RNS
AZ Reports Phase III Results for PT010 in COPD
26 Jan 2018 07:00 AM
RNS
AZ Reports Phase III Results for PT010 in COPD
19 Jan 2018 07:00 AM
RNS
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
19 Jan 2018 07:00 AM
RNS
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
12 Jan 2018 04:10 PM
RNS
FDA approves Lynparza for metastatic breast cancer
10 Jan 2018 03:10 PM
RNS
AstraZeneca's Fasenra approved in the EU
02 Jan 2018 03:00 PM
RNS
Total Voting Rights
28 Dec 2017 02:00 PM
RNS
Director/PDMR Shareholding
18 Dec 2017 07:00 AM
RNS
FDA accepts Tagrisso submission for 1st-line nsclc
15 Dec 2017 12:00 PM
RNS
Director/PDMR Shareholding
01 Dec 2017 03:00 PM
RNS
Block listing Interim Review
01 Dec 2017 03:00 PM
RNS
Total Voting Rights

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings